Biogen Inc. (NASDAQ:BIIB) is one of the top 10 medical AI companies to buy according to analysts. On July 14, UBS reiterated ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

We came across a bullish thesis on Biogen Inc. on r/Valueinvesting subreddit by U/Lobyous. In this article, we will summarize ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

Biogen (BIIB) delivered earnings and revenue surprises of +39.19% and +13.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the January 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...

Biogen BIIB and partner Sage Therapeutics SAGE completed the rolling submission of the new drug application (NDA) to the FDA for zuranolone for the potential treatment of major depressive disorder ...